Australia's most trusted
source of pharma news
Thursday, 12 February 2026
Posted 12 February 2026 PM
A world-first human clinical trial of Melius MicroBiomics’ genetically modified (GM) microbiome-based therapy for ulcerative colitis has been given the go-ahead by the Office of the Gene Technology Regulator (OGTR).
Vancouver-based biotech Melius MicroBiomics was founded in January 2023 off the back of University of British Columbia Okanagan Professor, Dr Deanna Gibson’s research.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.